Response to: Correspondence on ‘Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome’ by John E Madias

R. Citro, A. Silverio, M. Bellino, G. Parodi, E. Bossone
{"title":"Response to: Correspondence on ‘Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome’ by John E Madias","authors":"R. Citro, A. Silverio, M. Bellino, G. Parodi, E. Bossone","doi":"10.1136/heartjnl-2022-321278","DOIUrl":null,"url":null,"abstract":"To the Editor I enjoyed reading the article by Silverio et al, pertaining to the longterm (median followup of 24.0 months) effects of β-blocker therapy in patients with takotsubo syndrome (TTS). The authors employed a consecutive patient database of 825, studied over a 12year period, mostly female in their early 60s to late 70s from the Takotsubo Italian Network (TIN) registry, about 60% of whom were discharged on β-blockers, while the balance of patients did not receive such therapy, focusing on allcause mortality, TTS recurrence, and cardiac and noncardiac mortality as outcomes. While β-blockers did not influence TTS recurrence or cardiac mortality, they led to a reduction of allcause mortality, particularly for patients with hypertension and those who developed cardiogenic shock during the acute phase of TTS. The results reinforce the current belief that β-blockers do not have a specific effect in patients who have suffered TTS, in terms of prevention of its recurrence; also, it is not surprising that there was a beneficial effect of β-blockers in patients with hypertension and cardiogenic shock, considering the established indications for β-blocker therapy for patients with history of hypertension, coronary artery disease and heart failure. Considering the interest among Italian and other investigators on the effect of ACE inhibitors/ angiotensin receptor blockers, alone or in combination with β-blockers, on mortality and the recurrence of TTS, I would like to ask the authors if they have any information on the above for the patients in the TIN registry, and whether they recommend the use of ACE inhibitors/angiotensin receptor blockers, with or without β-blockers, for patients discharged after an index admission with TTS, as done by others. Also, since the TIN registry constitutes a multicentre (16 Italian hospitals) study of consecutive patients with TTS prospectively collected, fairly representative of the Italian population, it would be of interest to compare the observed prevalence of diabetes mellitus (DM) (11.9%) noted in the TIN registry with the prevalence of DM in the general Italian population, particularly in women in their early 60s to late 70s, considering previous work showing a low prevalence of DM in patients with TTS.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1242 - 1243"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/heartjnl-2022-321278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

To the Editor I enjoyed reading the article by Silverio et al, pertaining to the longterm (median followup of 24.0 months) effects of β-blocker therapy in patients with takotsubo syndrome (TTS). The authors employed a consecutive patient database of 825, studied over a 12year period, mostly female in their early 60s to late 70s from the Takotsubo Italian Network (TIN) registry, about 60% of whom were discharged on β-blockers, while the balance of patients did not receive such therapy, focusing on allcause mortality, TTS recurrence, and cardiac and noncardiac mortality as outcomes. While β-blockers did not influence TTS recurrence or cardiac mortality, they led to a reduction of allcause mortality, particularly for patients with hypertension and those who developed cardiogenic shock during the acute phase of TTS. The results reinforce the current belief that β-blockers do not have a specific effect in patients who have suffered TTS, in terms of prevention of its recurrence; also, it is not surprising that there was a beneficial effect of β-blockers in patients with hypertension and cardiogenic shock, considering the established indications for β-blocker therapy for patients with history of hypertension, coronary artery disease and heart failure. Considering the interest among Italian and other investigators on the effect of ACE inhibitors/ angiotensin receptor blockers, alone or in combination with β-blockers, on mortality and the recurrence of TTS, I would like to ask the authors if they have any information on the above for the patients in the TIN registry, and whether they recommend the use of ACE inhibitors/angiotensin receptor blockers, with or without β-blockers, for patients discharged after an index admission with TTS, as done by others. Also, since the TIN registry constitutes a multicentre (16 Italian hospitals) study of consecutive patients with TTS prospectively collected, fairly representative of the Italian population, it would be of interest to compare the observed prevalence of diabetes mellitus (DM) (11.9%) noted in the TIN registry with the prevalence of DM in the general Italian population, particularly in women in their early 60s to late 70s, considering previous work showing a low prevalence of DM in patients with TTS.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
回应:John E Madias关于“β受体阻滞剂与Takotsubo综合征患者更好的长期生存相关”的通信
对于编辑,我很喜欢阅读Silverio等人的文章,该文章涉及β-阻滞剂治疗takotsubo综合征(TTS)患者的长期(中位随访24.0个月)效果。作者使用了一个连续的825名患者数据库,对其进行了为期12年的研究,其中大多数是来自Takotsubo意大利网络(TIN)注册中心的60岁出头至70岁出头的女性,其中约60%的患者因服用β-阻滞剂而出院,而其余患者没有接受此类治疗,重点关注全因死亡率、TTS复发以及心脏和非心脏死亡率。虽然β-阻滞剂不会影响TTS复发或心脏死亡率,但它们降低了全因死亡率,尤其是对于高血压患者和在TTS急性期发生心源性休克的患者。研究结果强化了目前的观点,即β-受体阻滞剂在预防TTS复发方面对TTS患者没有特异性作用;此外,考虑到β受体阻滞剂治疗有高血压、冠状动脉疾病和心力衰竭病史的患者的既定适应症,β受体阻滞剂对高血压和心源性休克患者的有益作用也就不足为奇了。考虑到意大利和其他研究人员对ACE抑制剂/血管紧张素受体阻滞剂(单独或与β-阻滞剂联合使用)对TTS死亡率和复发的影响的兴趣,我想问作者,他们是否有关于TIN登记中患者的上述信息,以及他们是否建议像其他人一样,在TTS指数入院后出院的患者使用ACE抑制剂/血管紧张素受体阻滞剂,无论是否使用β-阻滞剂。此外,由于TIN登记是一项多中心(16家意大利医院)研究,对前瞻性收集的TTS连续患者进行研究,相当代表意大利人群,因此有兴趣将TIN登记中观察到的糖尿病(DM)患病率(11.9%)与意大利普通人群中的DM患病率进行比较,特别是在60出头到70出头的女性中,考虑到之前的研究显示TTS患者的DM患病率较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A retrospective review of empiric acyclovir prescribing practices for suspected viral central nervous system infections: A single-centre study. Cortical Morphology in Cannabis Use Disorder: Implications for Transcranial Direct Current Stimulation Treatment. Socioeconomic status and entrepreneurial networking responses to the COVID-19 crisis. Cardiac microstructural alterations measured by echocardiography identify sex-specific risk for heart failure. Aspirin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1